Why choose Worldwide as a partner in rare disease clinical research? Find out today: ow.ly/5nX550Pqp7I

Pharmacists play a critical role in ensuring patients and trial personnel remain safe in the early phases of your trial. Download our white paper to learn more. ow.ly/AmjB50PuUF2

Check out Jen Davis’s main takeaways after five days of informative conference sessions and networking at Psychedelic Science 2023. ow.ly/oaZY50PwLuI

Curious about what a biotech-focused CRO can do for you? Check out the ways Worldwide personalizes our approach for biotechs in our blog: ow.ly/Ezjs50Pzlig

Interested in using biomarkers to advance your clinical research? Discover how in our recent white paper: ow.ly/yPLm50PyPAF

Strong CRO-biotech partnerships can lead to expedited recruitment, enhanced retention, and improved scientific methodology. Find out how we enabled this with our collaboration on a Phase III ALS study: ow.ly/BjrU50PATKi

With an average of 11 years of experience supporting oncology development, our European team utilizes Worldwide’s global resources and local standards of care knowledge to optimize your trial design. Learn more about the team here: ow.ly/kruP50PAuIF

"Blockchain can be used for anything," according to our Aman Khera – including empowering patients. Learn more in this Clinical Leader article: ow.ly/JHKM50PBEP4

Check out the benefits of including patients in FDA engagement and the different ways patients can engage. ow.ly/v6Te50PCM1g

Registry studies can be used as an observational approach to understand the patient population in terms of the indication’s epidemiology, progression, and prevalence. Find out what else you can learn from registry studies in our article: ow.ly/ALUW50PCURM

Providing an overview of biomarker development within oncology, this white paper contains valuable insights into the future of oncology drug development: ow.ly/TeYf50PE1RO

At Worldwide, we offer comprehensive support services for Phase I and beyond. Check out our service offerings and let us know how we can help with your next study. ow.ly/ZV8W50PIvJZ

Get the customized and flexible support you need for your next program from our Cell & Gene Therapy Hub. Meet the team, and see how they adapt to fit your individual needs: ow.ly/LAFH50PLkCg

Find out how we managed the Phase III trial for the FDA-approved drug, lecanemab, for Alzheimer’s disease, which included more than 230 sites across 14 countries: ow.ly/cgGb50PM5bC

A vital part of our #EarlyPhase team is our Clinical Pharmacology Unit (CPU), recently accredited by CAP CAPathologists. Learn how this upholds our culture of quality and adds value for our customers: ow.ly/Z7oK50PLOWv

At this year’s Global Genes RARE Advocacy Summit, our Amy Raymond will present “Gene Replacement and Gene Editing Therapies” tomorrow at 10 AM. See more details here: ow.ly/SKwI50PMZaB

The oncology clinical trials market is experiencing explosive growth – and with growth comes barriers. In this ICT Magazine article, Teleen Norman and Clare Wallis explore how an integrated CRO/sponsor culture can help overcome these barriers. ow.ly/xwko50PNNJc

Interested in how we optimize our bioanalytical instruments? Check out how we expedite study timelines through our bioanalysis automation methods: ow.ly/wVxA50POklg

ASCPT Partner @WorldwideTrials is facilitating an innovative Idea Exchange at #ASCPT2025! bit.ly/3EJ4p81

We’re no longer posting on X, but our commitment to sharing insights and connecting with you continues. Follow us on LinkedIn to stay engaged with Worldwide Clinical Trials. We’ll see you there! 👇 linkedin.com/company/worldw…